CONFERENCE DAY TWO

9:20 am Chair’s Opening Remarks

9:20 am Check-In & Coffee

Applications of 3D Tissue Models to Support ADME & DMPK Studies

9:30 am Validating Skin-Based Complex In Vitro Models to Empower ADME & DMPK Predictions

Synopsis

  • Explaining how CIVM provide a more physiologically relevant environment for studying PK, bioavailability and more
  • Spotlighting strategies to ensure accurate recapitulation of the tissue microenvironment by using patient tissues
  • Linking in vitro data with in vivo data to assess for correlations and empower formulation decision-making

10:00 am Establishing Reproducible Neuromuscular-on-a-chip Models to Empower Efficacy Predictions

Synopsis

  • Showcasing the utilization of neuromuscular models to assess a spectrum of disorders including complement mediated, myotonic dystrophy, or immune-related responses
  • Uncovering lessons learned from employing a CIVM to assess for pharmacology and efficacy studies
  • Discussing how the efficacy assessments in neuromuscular models contribute to the optimization of candidate treatments, paving the way for enhanced interventions in the field

10:30 am Developing, Validating & Deploying in Vitro Models of the Central Nervous System to Inform Drug Development

Synopsis

  • Investigating the degree to which different in vitro models recapitulate the human and mouse CNS
  • Discussing how these models, paired with various assays, may predict drug-induced neurotoxicity
  • Presenting data suggesting that the right combination of model and assay can reveal unique insights into on- and off-target toxicity

Uncovering Optimized Strategies to Boost Toxicity Predictability Power Using Model Data

11:00 am Morning Break & Announcement of the Poster Awards

Synopsis

The winning posters for the two categories will be selected by our advisory board during the meeting. The winner will receive an engraved trophy and certificate, and have their poster showcased on our website as a downloadable file.

11:45 am Does the Complexity of In Vitro Models Matter?

Synopsis

  • Discussing the need to build robust protocols to enhance model reproducibility and empower their validation
  • Employing techniques to characterize organoid and ensure reproducibility and translatability for safety studies
  • Evaluating a range of innovative in vitro liver NAMs for AAV transduction efficiency and toxicity mechanisms

12:15 pm Empowering Oncology Drug Safety: Leveraging Reproducible Organ-on-a-Chip Models for Hazard Identification

Synopsis

  • Discussing the limitations of current models for assessing immunotoxicity of cell engagers and cell therapies
  • The ability of MPS model to mimic human physiological conditions, including cell-cell interactions and microenvironment dynamics, allows for more accurate predictions of drug responses
  • Case study: Assessing on-target off-tumor toxicity for T-cell engagers and cell therapy

12:45 pm Lunch Break

Exploring the Future of Modeling & Spotlighting Newer Tools to Empower Drug Discovery

1:30 pm Fireside Chat: Assessing the Future of 3D Tissue Modeling

  • Muriel Lize Scientific Expert – Immunology & Respiratory Discovery Sciences, Boehringer Ingelheim

Synopsis

  • Discussing the exciting model developments that have recently gained traction
  • Spotlighting the analysis tools like spatial biology to empower model validation

1:45 pm Applying Back Translation to Validate Complex In Vitro Models

  • Muriel Lize Scientific Expert – Immunology & Respiratory Discovery Sciences, Boehringer Ingelheim

Synopsis

  • Exploring optimized techniques to model lung pathobiology to develop a lung-in-a-dish model
  • Addressing the need for back translation of clinical compounds using emerging models to empower their validation
  • Spotlighting strategies to implement machine learning to empower compound screening and analysis

2:15 pm Harnessing Bioconvergence Including Validated MPS Data to Help Transform Drug Discovery & Development While Reducing Reliance on Animal Testing

  • Philip Hewitt Global Head of Early Investigative Toxicology, Merck

Synopsis

  • Utilizing bioconvergence to develop standardized methods for characterizing microphysiological systems, ensuring consistency and reliability across studies
  • Leveraging bioconvergence to empower prediction modeling in drug discovery
  • Collaborating with different functions to make the best out of the data outputs from this

2:45 pm Chair’s Closing Remarks & End of Summit